Auxilium risk/reward remains favorable, says UBS UBS continues to views Auxilium risk/reward favorable based on its growing business and potential for further indications for Xiaflex and business development. Shares are Buy rated with a $52 price target, up from $50.
Endo upgraded to Overweight from Neutral at Piper Jaffray Piper Jaffray upgraded Endo (ENDP) to Overweight with an $84 price target citing an improved asset base following the takeover of Auxilium (AUXL).
Auxilium downgraded to Neutral from Buy at Mizuho Mizuho downgraded Auxilium (AUXL) to Neutral following the company's agreement to be acquired by Endo (ENDP). The firm expects shareholders to approve the deal and does not expect a competing bid.